Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

@article{McNicholas2011MappingAC,
  title={Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).},
  author={Paul M. McNicholas and Paul A. Mann and Lisa Wojcik and Ping Qiu and Erin Lee and Michael K. McCarthy and Junwu Shen and Todd A. Black and Julie M Strizki},
  journal={Journal of acquired immune deficiency syndromes},
  year={2011},
  volume={56 3},
  pages={222-9}
}
OBJECTIVES In the phase 2 VICTOR-E1 study, treatment-experienced subjects receiving 20 mg or 30 mg of the CCR5 antagonist vicriviroc (VCV), with a boosted protease containing optimized background regimen, experienced significantly greater reductions in HIV-1 viral load compared with control subjects. Among the 79 VCV-treated subjects, 15 experienced virologic failure, and of these 5 had VCV-resistant virus. This study investigated the molecular basis for the changes in susceptibility to VCV in… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
8 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…